proving 213 (trading +1.9%) • Syngenta FY EBITDA light, EPS slight better, revs in line, div better, conf call +ve for Q1 (trading -1.4%) • Elan: Biogen to Pay Elan $3.25bn for the full rights to Tysabri (trading +10%) • Nokian Renkaat O4 miss buy dividend increase, +ve conf call sees 2013 ENIT slig

tment Management (to close in April). DDF is now seeking an additional £130M to reach its target I ttheimer's Research Department UK of Health Biogen A95tS2c. Tam de Olsuka 5 • • • • • • . a a •1 EFTA00799226 A roundabout, not a cascade :••: • Dementia • Discovery Fund • • 0

,250 88,450 Exxon Mobil XOM 10/15/18 10.000 813.881 808.000 -5.881 Lockheed Martin LMT 3/20/18 2,500 808,496 847,476 750,400 -97,076 Biogen !deo Inc BI03 2/14/12 2.095 250,455 7402184 495,216 -244,968 Goldman Sachs GS 1/25/18 1.850 499.873 414.844 355.182 -59.662 Karyophar

F.D.A. approval. Regardless of the risks, many drug companies are making huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cu

s from Akebia Therapeutics Inc, Alexion Pharmaceuticals. Alnylam Pharmaceuticals, AMAG Pharmaceuticals. Inc., Amgen. Inc., Auxilium Pharmaceuticals, Biogen Idec Inc. Celgene Corp, Chimerix Inc. Cubist Pharmaceuticals Inc.. Gilead Sciences Inc.. GW Pharmaceuticals PLC. ImmunoGen Inc.. Incyte Corporation

cl. Alzheimer's (2H14), Tysabri in SPMS (mid-2015), STX-100, Neublastin and Lupus. Guidance points to strong underlying growth for blz and stock — Biogen remains a top pick: Even without the AIFA benefit, guidance still incr. by -$1.30 or 11%. We've raised our 2014E/2015E EPS to $13.00/$16.28 from $

coml CC: Daniel Sabba I I: Ariane Dw Subject: BUB rCi Classification: Confidential Paul Morris Jeffrey — Rich suggested we reach out RE: your Biogen position. BUJ is up over 15% from last week to $475.08 currently. Note that you're long 2,095 shares, purchased on 2/14/2012 @ $119.5489 (unrealize

ial Jeffrey - _] Nav Gupta Vinit Sahni Just posting you on your biotech basket - earnings a positive catalyst reversing that downtrend in Gilead. Biogen reported this morning (bottom line miss, top-line beat), stock has come in from pre-market highs of $310, now -$303 (3-day chart below). Just a re

Classification: Confidential Jeffrey - Just posting you on your biotech basket - earnings a positive catalyst reversing that downtrend in Gilead. Biogen reported this morning (bottom line miss, top-line beat), stock has come in from pre-market highs of 5310, now — $303 (3-day chart below). Just a re

From: Richard Kahn Sent: Tuesday, August To: jeffrey E. Subject: Biogen Headlines coming across =rom WSJ that MRK/AGN have expressed =nterest in BIIB (link). BIIB is =9%. stock at 3:27pm is 330.90 you own 2,O95 shares

number of private investments. These have included Cerexa (NLV-I, exited in sale to Forest Labs, 5.4x multiple), Stromedix (NLV-I, exited in sale to Biogen Idec, 1.8x multiple plus milestones), Chimerix (NLV-IL, IPO - April, 2013, NASDAQ: CMRxX), and Auxilium (Sprout IX, NASDAQ: AUXL, exited at 4.6x). e